March 2008
Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p7
Trade Publication
This article reports on the positive opinion received by the International Myeloma Foundation (IMF) from the European Medicines Agency (EMEA) that could lead to a new treatment regimen for older people in Europe. An approval recommendation was given for Thalidomide Pharmion in combination with melphalan and prednisone. Comments from Susie Novis, president and co-founder of the IMF, are included. Particular focus is given to the safety issue faced by thalidomide in the U.S.


Related Articles

  • Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department? El Mahou, S.; Attal, M.; Jamard, B.; Constantin, A.; Cantagrel, A.; Mazières, B.; Arnaud, C.; Laroche, M. // Clinical Rheumatology;Apr2006, Vol. 25 Issue 2, p175 

    Survival of patients with multiple myeloma (MM) showed no improvement between the 1960s and 1990s. During the last decade, new therapeutic approaches seemed likely to offer hope of prolonging survival. The aim of this study was to examine if this survival increased with the usage of new...

  • Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report. Wöhrer, Stefan; Ackermann, Jutta; Baldia, Catrin; Seidl, Sonj A.; Raderer, Markus; Simonitsch, Ingri; Drach, Johannes // Hematology Journal;2004, Vol. 5 Issue 4, p361 

    Plasma cell leukemia (PCL) is an aggressive disease with poor prognosis and a median survival of only 2-6 months. Currently, no standard therapy is available, but intensive polychemotherapy appears to be more effective than the conventional melphalan plus prednisone. However, the efficacy of...

  • Multiple Myeloma: New Options, New Challenges. Lacy, Martha Q. // Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p877 

    The article focuses on the development concerning treatment of multiple myeloma. Along with the development is the emergence of new combination regimens in treating the disease. Some of the combination therapies are the pegylated liposomal doxorubicin, vincristine and decreased-frequency...

  • Solid tumors in multiple myeloma. Stegman, Roger; Alexanian, Raymond; Stegman, R; Alexanian, R // Annals of Internal Medicine;May79, Vol. 90 Issue 5, p780 

    The frequency of solid tumors was evaluated in 628 consecutive patients with multiple myeloma who had been treated with various melphalan-prednisone combinations. Among those patients who lived at least 2 months, the incidence and diversity of second tumors were similar to those in normal...

  • Thalidomide approved for multiple myeloma.  // WHO Drug Information;2008, Vol. 22 Issue 1, p19 

    The article reports on the approval of Thalimodine Pharmion thalidomide drug for the treatment of multiple myeloma by the European Medicines Agency (EMEA) in Europe. EMEA has approved the drug for the treatment of bone marrow cancer multiple myeloma. Results of clinical studies prove that adding...

  • New Perspectives in the Treatment of Elderly Patients with Newly Diagnosed Multiple Myeloma. Ofidani, Massimo; Corvatta, Laura; Gentili, Silvia; Piersantelli, Maria-novella; Polloni, Claudia; Leoni, Pietro // Current Medical Literature: Leukemia & Lymphoma;2009, Vol. 17 Issue 2, p29 

    The article discusses the treatment options for multiple myeloma (MM) in elderly patients aged 65 and older. Conventional treatments such as melphalan and prednisone, and high-dose dexamethasone are discussed. Results of clinical trials for new treatments such as autologous stem cell...

  • Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Verelst, Silvia; Termorshuizen, F.; Uyl-de Groot, C.; Schaafsma, M.; Ammerlaan, A.; Wittebol, S.; Sinnige, H.; Zweegman, S.; Marwijk Kooy, M.; Griend, R.; Lokhorst, H.; Sonneveld, P.; Wijermans, P. // Annals of Hematology;Dec2011, Vol. 90 Issue 12, p1427 

    Thalidomide with melphalan/prednisone (MPT) was defined as standard treatment in elderly patients with multiple myeloma (MM) based on five randomized trials. In one of these trials, HOVON49, a prospective health-related quality-of-life (HRQoL) study was initiated in order to assess the impact of...

  • Treatment patterns and outcomes in elderly patients with multiple myeloma. Bang, S-M; Kyle, R A; Rajkumar, S V; Kumar, S // Leukemia (08876924);Apr2013, Vol. 27 Issue 4, p971 

    This article discusses a study which examined treatment patterns and outcomes among elderly patients with multiple myeloma (MM) who were seen at the Mayo Clinic in Rochester, Minnesota between January 1999 and December 2008. The study findings showed that MM has a more malignant biology in...

  • Continuous Low Dose of Melphalan and Prednisone in Patients with Multiple Myeloma of Very Old Age or Severe Associated Disease. Pulsoni, A.; Villivà, N.; Cavalieri, E.; Falcucci, P.; La Verde, G.; Matera, R.; Petrucci, M.T.; Tosti, M.E.; Mandelli, F. // Drugs & Aging;2002, Vol. 19 Issue 12, p947 

    Introduction and Objective: The management of elderly patients with multiple myeloma is a relevant problem because it concerns a great number of patients. Patients with multiple myeloma who are very old or who have severe associated diseases have a dismal outcome. For these patients we...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics